For the first time in its history, the European Society for Medical Oncology (ESMO) dedicated an entire track to Artificial Intelligence (AI) at its 2025 conference. For those who partner with pharmaceutical and biotech companies to bring their innovations to market, this was a landmark moment. It signaled a definitive shift from AI as a theoretical novelty to a practical force in the fight against cancer.
The overarching theme was not one of unbridled hype, but rather a nuanced narrative of opportunity and obstacles. From the perspective of a commercialization partner, this duality is not a sign of weakness, but a map for the strategic path forward. From breakthroughs in diagnostics and clinical trials to candid discussions about data, equity and trust, the conference revealed a landscape rich with opportunity—and complexity.
For those shaping the future of cancer care, the path forward is both exciting and demanding. Curious about the real impact of AI in oncology and what’s next for commercialization?
Download the POV to discover the insights, obstacles and strategies that are shaping tomorrow’s breakthroughs.
Author
Barry Vucsko has more than 25 years of marketing, advertising, and consulting experience spanning more than 100 brands and several continents...